Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


NK cell deficiency syndromes: Clinical manifestations and diagnosis

INTRODUCTION

Natural killer (NK) cells are non-T, non-B lymphocytes that are critical in defense against virally-infected cells and in tumor surveillance [1-3]. These cells are considered part of the innate immune system because they do not require previous exposure to foreign, pathogenic, or dangerous antigens to act.

The importance of NK cells in human health and disease is illustrated by a small number of human diseases in which NK cells are absent or defective. These conditions are characterized primarily by severe, recurrent, or atypical infections with herpes viruses.

The biology of NK cells, the clinical manifestations of isolated NK cell deficiency syndromes, the evaluation of patients suspected to have these disorders, and the differential diagnosis will be discussed here. The management of patients with NK cell deficiency syndromes is presented separately. (See "NK cell deficiency syndromes: Treatment".)

BIOLOGY OF NK CELLS

Natural killer (NK) cells are lymphocytes that originate in the bone marrow that comprise 5 to 10 percent of the peripheral blood lymphocyte pool [4]. Although low in number, they are the main lymphocytes of the innate immune system in the peripheral blood. NK cells account for a minority of lymphocytes within organs in most cases, although there are important exceptions. In the duodenal epithelia and in the uterine decidua during pregnancy, NK cells account for up to 45 and 70 percent of lymphocytes, respectively [5,6].

Phenotypic characteristics — NK cells differ phenotypically from other lymphocytes by the presence of large cytoplasmic granules (picture 1).

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Aug 20, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29:1157.
  2. Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17:189.
  3. Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006; 118:1.
  4. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187.
  5. Eiras P, Roldán E, Camarero C, et al. Flow cytometry description of a novel CD3-/CD7+ intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease. Cytometry 1998; 34:95.
  6. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol 2006; 6:584.
  7. Cederbrant K, Marcusson-Ståhl M, Condevaux F, Descotes J. NK-cell activity in immunotoxicity drug evaluation. Toxicology 2003; 185:241.
  8. Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:399.
  9. Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055.
  10. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003; 188:948.
  11. Lee SJ, Cho YN, Kim TJ, et al. Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 2012; 64:2868.
  12. Strowig T, Brilot F, Münz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008; 180:7785.
  13. Biassoni R, Cantoni C, Pende D, et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001; 181:203.
  14. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21:483.
  15. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11:237.
  16. Orange JS, Fassett MS, Koopman LA, et al. Viral evasion of natural killer cells. Nat Immunol 2002; 3:1006.
  17. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008; 8:259.
  18. Stebbins CC, Watzl C, Billadeau DD, et al. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003; 23:6291.
  19. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197.
  20. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol 2005; 5:363.
  21. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007; 19:339.
  22. Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007; 19:301.
  23. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8:713.
  24. Hanna J, Bechtel P, Zhai Y, et al. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 2004; 173:6547.
  25. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731.
  26. Wendland T, Herren S, Yawalkar N, et al. Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia. Immunol Lett 2000; 72:75.
  27. Etzioni A, Eidenschenk C, Katz R, et al. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr 2005; 146:423.
  28. Notarangelo LD, Mazzolari E. Natural killer cell deficiencies and severe varicella infection. J Pediatr 2006; 148:563.
  29. Akiba H, Motoki Y, Satoh M, et al. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol 2001; 11:58.
  30. Ballas ZK, Turner JM, Turner DA, et al. A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset. J Allergy Clin Immunol 1990; 85:453.
  31. Shaw RK, Issekutz AC, Fraser R, et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 2012; 119:4009.
  32. Bernard F, Picard C, Cormier-Daire V, et al. A novel developmental and immunodeficiency syndrome associated with intrauterine growth retardation and a lack of natural killer cells. Pediatrics 2004; 113:136.
  33. Eidenschenk C, Jouanguy E, Alcaïs A, et al. Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. J Immunol 2006; 177:8835.
  34. Eidenschenk C, Dunne J, Jouanguy E, et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet 2006; 78:721.
  35. Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115:1519.
  36. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118:2653.
  37. Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118:2656.
  38. Mace EM, Hsu AP, Monaco-Shawver L, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 2013; 121:2669.
  39. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43:929.
  40. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43:1012.
  41. Wieser R, Volz A, Vinatzer U, et al. Transcription factor GATA-2 gene is located near 3q21 breakpoints in myeloid leukemia. Biochem Biophys Res Commun 2000; 273:239.
  42. Orange JS. Unraveling human natural killer cell deficiency. J Clin Invest 2012; 122:798.
  43. Hughes CR, Guasti L, Meimaridou E, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 2012; 122:814.
  44. Gineau L, Cognet C, Kara N, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest 2012; 122:821.
  45. Grier JT, Forbes LR, Monaco-Shawver L, et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012; 122:3769.
  46. Jawahar S, Moody C, Chan M, et al. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996; 103:408.
  47. de Vries E, Koene HR, Vossen JM, et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996; 88:3022.
  48. de Haas M, Koene HR, Kleijer M, et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol 1996; 156:2948.
  49. Aoukaty A, Lee IF, Wu J, Tan R. Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells. J Clin Immunol 2003; 23:141.
  50. Fleisher G, Starr S, Koven N, et al. A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr 1982; 100:727.
  51. Lopez C, Kirkpatrick D, Read SE, et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J Infect Dis 1983; 147:1030.
  52. Komiyama A, Kawai H, Yabuhara A, et al. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Pediatrics 1990; 85:323.
  53. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15:199.
  54. Texas Children's Hospital, Houston, TX (Dr. Jordan Orange); Cincinnati Children's Hospital Medical Center, Cincinatti, Ohio (Dr. Alexandra (Lisa) H. Filipovich); University of Iowa, Iowa City, Iowa (Dr. Zuhair Ballas); Universita degli studi di Brescia, Italy (Dr. Raffaele Badolato).
  55. Academic centers include the University of Iowa, Cincinnati Children's Hospital, and Children's Hospital of Philadelphia.
  56. One commercial laboratory that performs this test is the Cincinnati Children's Hospital Diagnostic Immunology Laboratory. Search on "CD107a" in the test menu. http://www.cincinnatichildrens.org/service/c/cancer-blood/hcp/diagnostic-lab/default/ (Accessed on June 18, 2013).
  57. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119:2754.
  58. GATA2 mutational analysis is available from Prevention genetics (search by gene using term "GATA2"). www.Preventiongenetics.com (Accessed on July 15, 2013).
  59. Nair MP, Schwartz SA. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol 1984; 132:2876.
  60. Botzler C, Kis K, Issels R, Multhoff G. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets. Exp Hematol 1997; 25:338.
  61. Nair MP, Kronfol ZA, Schwartz SA. Effects of alcohol and nicotine on cytotoxic functions of human lymphocytes. Clin Immunol Immunopathol 1990; 54:395.
  62. Knight SC, Harding B, Burman S, Mertin J. Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression. Clin Exp Immunol 1981; 46:61.
  63. Roder JC, Klein M. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol 1979; 123:2785.
  64. Hall TJ, Chen SH, Brostoff J, Lydyard PM. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol 1983; 54:493.
  65. Specter S, Rivenbark M, Newton C, et al. Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. Int J Immunopharmacol 1989; 11:63.
  66. Ausiello CM, Barbieri P, Spagnoli GC, et al. In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin Exp Rheumatol 1986; 4:255.
  67. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002; 4:1545.
  68. Wood SM, Ljunggren HG, Bryceson YT. Insights into NK cell biology from human genetics and disease associations. Cell Mol Life Sci 2011; 68:3479.
  69. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.
  70. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957.
  71. Koren HS, Amos DB, Buckley RH. Natural killing in immunodeficient patients. J Immunol 1978; 120:796.
  72. Russell AS, Miller C. The activity of natural killer cells in patients with rheumatoid arthritis: I. The effect of drugs used in vivo. Clin Exp Rheumatol 1984; 2:227.
  73. Fujimiya Y, Bakke A, Chang WC, et al. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1. Int J Cancer 1986; 37:639.
  74. Ullum H, Gøtzsche PC, Victor J, et al. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J Exp Med 1995; 182:789.
  75. Corado J, Toro F, Rivera H, et al. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 109:451.